Introduction
Control of a number of cellular processes, including epithelial proliferation and dierentiation, have been shown to be highly dependent upon phosphorylation events (Hunter, 2000) . Several kinases participating in many signal transduction pathways have been identi®ed as key players in the phosphorylation of many cell surface receptors or cell adhesion molecules (Gumbiner, 2000) . Additionally, several cell adhesion molecules such as the cadherins or N-CAM play an important role in preventing the development or dissemination of colon cancer (Kinzler and Vogelstein, 1996; Gumbiner, 2000) . Biliary glycoprotein (Bgp) is a member of the carcinoembryonic antigen (CEA) family. The nomenclature of this large gene family has recently been revised and Bgp is now referred to as CEACAM1. CEACAM1 is an immunoglobulin (Ig)-like protein bearing either two or four Ig-like extracellular domains. It is anchored to the cell membrane and associates tightly with the actin cytoskeleton (Sadekova et al., 2000) . It is expressed with two variants of its cytoplasmic domain, known as either the short (CEACAM1-S: 10 amino acids) or long tail (CEACAM1-L: 71 ± 73 amino acids). These dierent isoforms result from alternative splicing events of the CEACAM1 gene and are well conserved in dierent species (Barnett et al., 1989; Najjar et al., 1993; NeÂ dellec et al., 1995) . CEACAM1 is generally expressed in epithelial cells of the gastro-intestinal tract, in hepatocytes as well as in endothelial and hemopoietic cells (Beauchemin and Lin, 1998) .
CEACAM1 is down-regulated in microadenoma and adenoma phases of tumorigenesis (Neumaier et al., 1993; Nollau et al., 1997; Ilantzis et al., 1997) . We have provided evidence that introduction of CEACAM1-L into a tumorigenic mouse colon carcinoma cell line (CT51), lacking in its expression, led to abrogation of in vivo tumor development (Kunath et al., 1995) . This phenotype was entirely dependent upon the presence of the CEACAM1 protein with the longer cytoplasmic tail, as cells expressing CEACAM1-S behaved essentially as the wild-type cells. Similar results have been obtained using prostate and breast carcinoma models Luo et al., 1997) . A number of residues within the longer domain participate in this phenotype: in particular, a single point mutation of Tyr488, conforming to an Immuno-receptor Tyrosine Inhibition Motif (ITIM), was sucient to reverse the in vivo tumor cell growth inhibition. In addition, three lysines in the C-terminal region were essential for the CEACAM1-L-mediated tumor inhibitory phenotype .
CEACAM1 performs other cellular functions. It was shown to function as an adhesion molecule (Ocklind and Obrink, 1982; Rojas et al., 1990 Rojas et al., , 1996 McCuaig et al., 1992) . Formisano et al. (1995) demonstrated that rat CEACAM1 (also known as pp120 or HA4) is involved in internalization of the insulin receptor. In the mouse, CEACAM1 acts as the mouse hepatitis virus receptor (Dveksler et al., 1991) , whereas it serves as a receptor for a number of Neisseria gonoccoci in human neutrophils (Virji et al., 1996; Gray-Owen et al., 1997) . Moreover, we have recently shown that CEACAM1 participates in signal transduction events mediated by Tyr phosphorylation of its cytoplasmic domain, particularly at residue Tyr488 . Tyr488 phosphorylation is induced by Src-like kinases or the insulin receptor (Rees-Jones and Taylor, 1985; Brummer et al., 1995) and is controlled in part by residues located at the carboxy-terminal region of the CEACAM1 cytoplasmic domain (Huber et al., 1999) . Enhanced Tyr phosphorylation of CEACAM1-L results in recruitment of the cytosolic Tyr phosphatases SHP-1 and SHP-2 to the cell surface where they bind to and dephosphorylate CEACAM1-L Huber et al., 1999) . Hauck et al. (1998) have also determined that activation of CEACAM1 in neutrophils by a recombinant Neisseria opa 52 protein induced its Tyr phosphorylation by the Fgr and Hck Tyr kinases leading to activation of Rac1, PAK and the Jun-N-terminal kinase.
Many Ser/Thr kinase consensus sites are present within the CEACAM1 cytoplasmic domain such as those for cAMP-dependent protein kinase, calmodulin kinase, p34cdc2 and glycogen synthase kinase 3 (Edlund et al., 1998) . In addition, 13 out of the 17 Ser and Thr in CEACAM1-L represent potential PKC phosphorylation consensus sequences (Edlund et al., 1998) . Odin et al. (1986) have demonstrated that CEACAM1 was basally phosphorylated on Ser and Thr residues. More recently, in vitro Ser phosphorylation of the cytoplasmic domain of CEACAM1 mediated by the protein kinase C (PKC) b2 isoform has been reported. In this study, the use of synthetic peptides mimicking the Ser449 environment has identi®ed this residue as the PKC phosphorylated residue (Edlund et al., 1998) .
Relatively little is known about the Ser/Thr kinases controlling CEACAM1 functions. CEACAM1-L-dependent internalization of the insulin receptor requires phosphorylation of Tyr488 and Ser503 on the cytoplasmic domain of CEACAM1-L . In addition, CEACAM1-L-mediated bile acid eux requires Ser503 phosphorylation and is regulated by Tyr488 (Sippel et al., 1994) . As Ser503 has been described as functionally important in many cellular or functional contexts, we questioned whether it played a signi®cant role in inhibition of tumor development. Our results show that Ser503 is crucial for this phenotype. We also demonstrate that the wild-type CEACAM1-L is basally phosphorylated and that the phosphorylation is enhanced in vivo after phorbol ester treatment of either mouse CT51 colon carcinoma cells, mouse 1MEA 7R.1 liver carcinoma cells or human 293 embryonic kidney cells. Basal or PMA-induced CEACAM1-L Ser phosphorylation is not dependent upon protein kinase C activity as treatment with calphostin C, a speci®c PKC inhibitor, did not change the phosphorylation of the protein. Other inhibitors to dierent Ser/Thr kinases similarly had no eect on overall levels of CEACAM1-L Ser phosphorylation. The Ser503Ala mutation does not dramatically alter the basal or PMA-induced CEACAM1-L phosphorylation. Furthermore, PMA treatment of CT51 cells caused cell spreading and relocalization of wild-type CEACAM1-L, but mutation at Ser503 did not change this behavior.
Results

Ser503 is essential for CEACAM1-dependent inhibition of tumor cell development
We have previously demonstrated that the long cytoplasmic domain of the CEACAM1 protein is crucial for inhibition of mouse colon tumor cell development (Kunath et al., 1995) . Similar results have also been obtained in prostate, breast and bladder carcinoma models Kleinerman et al., 1995; Luo et al., 1997) . Ser503 has been shown to play a crucial role in insulin receptor internalization and in bile salt extrusion (Sippel et al., 1994) . We therefore investigated the role of Ser503 in CEACAM1-Lmediated tumor inhibition. The Ser503 residue was mutated to an Ala and, after retroviral-mediated infections with the CEACAM1-L Ser503 vector, CT51 cells expressing this mutant protein were derived. We veri®ed that the protein was expressed at the surface of CT51 cells by staining with anti-CEACAM1 antibodies and determined the levels of expression over background by FACS analyses (Figure 1b) . We have previously demonstrated that in vivo inhibition of tumor development required physiological' levels of CEACAM1 expression and therefore CT51 cell populations expressing CEACAM1 at approximately 2 ± 4-fold over background were selected for these assays. Two independent tumor assays were conducted with transfected CT51 cell populations injected into syngeneic BALB/c mice (minimum of 10 mice/ experiment). As shown in Table 1 , the CT51 parental cells, the control transfected cells (neo) or cells expressing a natural variant of the CEACAM protein containing a short cytoplasmic domain (CEACAM1-S) developed a substantial number of tumors during the 42 ± 56 days of the in vivo tumor assays. No signi®cant inhibition of tumor development was seen relative to the parental cells with either the neo control cells or cells expressing the CEACAM1-S natural variant (P40.05), as reported previously (Kunath et al., 1995) . On the other hand, only 31% (P=0.002) of the mice injected with CT51 cell population expressing the wild-type CEACAM1-L protein developed tumors (Table 1) (Kunath et al., 1995; Izzi et al., 1999) . When CT51 cell populations expressing the Ser503 point mutant were injected into mice, 18/20 mice developed tumors ( 
Phosphorylation of the CEACAM1-L protein in epithelial cells
CEACAM1-L is basally phosphorylated on Ser and Thr residues in rat hepatocytes and this phosphorylation is enhanced in PMA-treated transfected COS cells (Odin et al., 1986; McEntire et al., 1989; Culic et al., 1992; Sippel et al., 1994) . Maximal enhancement of phosphorylation was noticed at PMA concentrations greater than 250 nM, although a net increase was also observed at 25 nM (data not shown). Therefore, PMA induced phosphorylation of the mouse CEACAM1-L protein in human or mouse epithelial cells.
Effect of Ser/Thr protein kinase inhibitors on CEACAM1-L phosphorylation
It has previously been suggested that either protein kinase C or protein kinase A might be involved in in vivo or in vitro CEACAM1-L phosphorylation (Lin and Guidotti, 1989; Sippel et al., 1994) . Edlund et al. (1998) demonstrated that a membrane-proximal site (SRKS/T), present in the CEACAM1 short cytoplasmic domain, was phosphorylated in vitro after incubation with the PKC b2 isoform. In our system, we have also observed the stimulation of CEACAM1-L phosphorylation by PMA treatment, known to activate P-orthophosphate and treated with the phorbol ester PMA at concentrations of 200 or 500 nM for 10 min. Cells were lysed and CEACAM1-L was collected from 500 mg of total cell lysate proteins by immunoprecipitation with the monoclonal CC1 antibody. Immune complexes were collected and the proteins were separated by SDS ± PAGE electrophoresis. Dried gels exposed to X-ray ®lms. 1MEA7R.1-neo cells correspond to cells transfected with the empty vector protein kinase C (Newton, 1994) . Consequently, we ®rst investigated the eect of protein kinase C inhibitors on in vivo CEACAM1-L phosphorylation. Cells were metabolically labeled for 2 h with 32 Porthophosphate. At the end of this period, either staurosporine (1 or 5 mM) or the protein kinase Cspeci®c inhibitor calphostin C (1 mM) (Kobayashi et al., 1989) , was added to the media for 15 min prior to the 10 min treatment with PMA (250 or 500 nM).
When CT51 transfected cells were incubated with staurosporine, both untreated and PMA-treated cells demonstrated a signi®cant reduction of the CEACAM1-L Ser phosphorylation levels ( Figure 3a , lanes 3 and 4 versus lanes 1 and 2). However, the protein kinase C-speci®c inhibitor calphostin C, did not lead to reduction of the Ser phosphorylation. Similarly, the H7 and sphingosine inhibitors which have been shown to have inhibitory eects towards protein kinase C (Casnellie, 1991) , did not aect either basal or PMA-induced CEACAM1-L phosphorylation (data not shown). The levels of CEACAM1-L expressed were identical as can be judged in the immunoblot (Figure 3b) . Therefore, the protein kinase responsible for CEACAM1-L phosphorylation was sensitive to staurosporine and resistant to calphostin C and other protein kinase C inhibitors.
As 13 Ser/Thr residues on the mouse CEACAM1-L cytoplasmic domain are positioned within consensus sequences for Ser/Thr phosphorylation (Kennely and Krebs, 1991; Edlund et al., 1998) , we examined a number of potential kinases known to be sensitive to staurosporine (Gschwendt et al., 1994) . There are two binding sites for calmodulin on the CEACAM1-L cytoplasmic domain (Edlund et al., 1996) and therefore, the KN-62 inhibitor of calmodulin kinase was tested. No decrease of basal or PMA-induced Ser phosphorylation was noticed (Figure 3a , lanes 7 and 8). Neither were changes observed when the RP-cAMP, a speci®c inhibitor of protein kinase A was used (Figure 3a , lanes 9 and 10). Similar results were obtained with the BNL 1MEA 7R.1 mouse liver carcinoma cells stably transduced with the CEACAM1-L cDNA construct (data not shown). Therefore, CEACAM1-L phosphorylation is sensitive to staurosporine; however, the staurosporine-sensitive kinase(s) using CEACAM1-L as a substrate remains to be identi®ed.
Is the CEACAM1-L Ser503 residue a site of Ser phosphorylation in vivo?
Ser503 in the rat CEACAM1-L cytoplasmic domain is known to be phosphorylated and was shown to participate in either bile salt extrusion or internalization of the insulin receptor (Sippel et al., 1994; Formisano et al., 1995) . Hence, we investigated whether Ser503 was a major phosphorylation site in mouse CEACAM1-L. The Ser503 residue was converted to a non-phosphorylatable Ala residue and this mutant was stably transduced into CT51 cells and a number of cell clones were isolated and selected for CEACAM1-L/Ser503 expression by FACS analysis. The level of basal or PMA-induced phosphorylation was evaluated in the resultant cell lines (Figure 4) . PMA treatment of a representative cell clone expressing the wild-type CEACAM1-L increased its levels of phosphorylation by threefold (Figure 4a ,b, lanes 1 and 2; 4c, lanes 1 and 4). When a CT51 cell line expressing the Ser503 mutant was treated with PMA, an increase in Ser/Thr phosphorylation levels was also observed (Figure 4a ,b, lanes 3 and 4; 4c, lanes 7 and 9), although this increase was generally by a factor of 1.5 ± 2-fold. This result suggests that the mouse Ser503 does not constitute the unique site of Ser phosphorylation by the PMA-inducible kinase(s).
As previously noticed, staurosporine completely inhibited basal Ser phosphorylation levels of the wildtype CEACAM1-L protein ( Figure 4c In vitro phosphorylation of CEACAM1-L As our in vivo data diered from the in vitro results with the rat CEACAM1-L (Edlund et al., 1998) , we proceeded to verify whether the mouse CEACAM1-L cytoplasmic domain could indeed be phosphorylated in vitro by protein kinase C and if so, which sites were preferentially used by this kinase. A number of glutathione S-transferase fusion proteins expressing either the short-or full-length, mutated or deleted P-orthophosphate and treated with the indicated inhibitors for 15 min as described in Materials and methods. The cells were then treated with the phorbol ester PMA at 500 nM for 10 min, lysed and CEACAM1-L was collected from 500 mg of total cell lysate proteins by immunoprecipitation with the monoclonal CC1 antibody. Immune complexes were collected, the proteins were separated by SDS ± PAGE electrophoresis, transferred to Immobilon membranes and immunoblotted with the polyclonal 2456 anti-CEACAM1 antibody. The membranes were subsequently exposed to X-ray ®lms and quanti®ed using a Fuji BioImager. (a) autoradiogram. (b) immunoblot. Stau., staurosporine long CEACAM1 cytoplasmic domains ( Figure 1a ) were subjected to in vitro kinase assays using puri®ed protein kinase C a, b and g isoforms. As seen in Figure  5a , all GST fusion proteins expressing either CEACAM1 cytoplasmic domain were phosphorylated by the puri®ed protein kinase C isoforms, whereas glutathione S-transferase remained unphosphorylated. Even the shortest CEACAM1-L deletion mutant, terminating at amino acid 461 (Figure 1a, D461) , was adequately phosphorylated in these conditions, suggesting that minimally, the membrane-proximal site (SRKS) was recognized by protein kinase C. To con®rm whether other protein kinase C sites in the long cytoplasmic domain were also used in vitro, tryptic maps of the in vitro 32 P-labeled GST fusion proteins expressing the CEACAM1 mutants were performed. In all cases, the same pattern showing two 32 P-labeled peptides was observed (Figure 5b ). To determine that these two peptides were identical in all cases, they were collected from all thin layer chromatography plates, eluted from the matrix and the resulting mix of peptides re-run on a TLC plate. This gave rise to the same chromatogram shown in Figure 5b . These results indicate that the membraneproximal SRKS site is phosphorylated in vitro by protein kinase C. In addition, these results con®rm that this site constitutes the unique in vitro protein kinase C site in the long cytoplasmic domain of CEACAM1-L.
PMA treatment of CT51 cells leads to CEACAM1-L relocalization
It has previously been shown that CEACAM1-L's membrane localization and its association with the actin cytoskeleton correlated with its tumor inhibitory phenotype (Sadekova et al., 2000) . It has also been shown that PMA provokes diverse phenotypic eects on cell morphology, spreading and motility and relocalization of E-cadherin in MDCK cells (Imamura et al., 1998; Kamei et al., 1999) . We questioned whether PMA treatment of CT51 cells would change the localization or solubility of CEACAM1-L or its Ser503 mutant derivative. As shown in Figure 6a , in untreated CT51 cells expressing wild-type CEACAM1-L, the protein was found at the cell ± cell contacts (Figure 6a, panel 1) . We have previously demonstrated that it is then in tight association with cortical actin Figure 4 Response of the Ser503 CEACAM1-L mutant to PMA stimulation and inhibitors. Wild-type (2L12) or Ser503-mutated (Ser66) CEACAM1-L-transfected CT51 cell clones were metabolically labeled with 32 P-orthophosphate. The cells were then treated with the phorbol ester PMA at 500 nM for 10 min, lysed and CEACAM1-L was collected from 500 mg of total cell lysate proteins by immunoprecipitation with the monoclonal CC1 antibody. Immune complexes were collected, the proteins were separated by SDS ± PAGE electrophoresis and transferred to Immobilon membranes. The membranes were subsequently exposed to X-ray ®lms and the protein bands were quanti®ed using a Fuji BioImager. Figure 5 In vitro PKC phosphorylation. (a) Samples of 10 ng of the puri®ed PKC a, b and g isoforms were used in in vitro kinase assays to phosphorylate 100 ng of the short or long CEACAM1-L cytoplasmic domains or point and deletion mutants (identity in Figure 1a ) produced as GST fusion proteins in bacteria as described in Materials and methods. Resulting proteins were separated on 10% SDS ± PAGE gels and either exposed directly to X-ray ®lms (top) or immunoblotted with an anti-GST antibody (bottom). (b) Labeled proteins were extracted from the gels and subjected to trypsin cleavage. Resulting peptides were separated on TLC plates in two-dimensions according to van der Geer et al., 1994
Figure 6 Treatment of cells with PMA leads to CEACAM1-L relocalization. (a) CT51 cells transfected with either the wild-type (panels 1 ± 6) or Ser503 mutant (panels 7 and 8) were either untreated (panels 1, 2 and 7) or treated with PMA (panels 3 ± 6 and 8) for 15 min. Cells were also treated with the staurosporine (stauro.) or calphostin C inhibitors for 15 min prior to addition of PMA (panels 5 and 6). The cells were then processed for immuno¯uorescence as described in Materials and methods. PMA led to the relocalization of the CEACAM1-L protein from the cell contacts. This was inhibited by staurosporine, but not by calphostin C. (b) Confocal sectioning was performed on CEACAM1-L-transfected CT51 cells to examine localization of CEACAM1-L after PMA treatment. The protein is present in a ring-like structure at the top of the cells. (c) CEACAM1-L solubility after PMA treatment. A wild-type CEACAM1-Lexpressing clone (2L12) was either untreated (lanes 1 and 2) or treated for a short (lanes 3 and 4) or prolonged (lanes 5 and 6) period with 500 nM of PMA. Cells were collected in a 1% Triton X-100-containing buer as previously described (Sadekova et al., 2000) . CEACAM1-L was collected by immunoprecipitation with the CC1 Ab from the soluble and insoluble fractions. The proteins were electrophoresed on 8% SDS ± PAGE gels and revealed using an anti-CEACAM1 polyclonal Ab (Sadekova et al., 2000) (Figure 6a , panel 2). The expression of CEACAM1-L at cell ± cell contacts was con®rmed by confocal Z-sectioning through a representative cell cluster (Figure 6b , panels 1 ± 6). In comparison, no signi®cant dierences in cellular localization of the Ser503 mutant protein were noticed relative to that of the wild-type CEACAM1-L ( Figure  6a , panels 7 and 8 compared to panels 1 and 3). However, treatment of CT51 transfected cells with PMA for 15 min led to a dramatic¯attening and spreading of the cells (Figure 6a, panel 3) . In addition, CEACAM1-L was no longer present at cell contacts, but appeared diuse as speckles condensed in a perinuclear ring as seen by confocal Z-sectioning (Figure 6b , panels 7 ± 12: magni®cation identical to that of panels 1 ± 6). Importantly, the actin cytoskeleton was also aected by the PMA treatment as phalloidin staining was co-incident with that of CEACAM1-L (Figure 6a , panel 4). To determine whether CEACAM1-L was localized intracellularly, PMA-treated CEACAM1-L-expressing CT51 cells were immunostained before or after permeabilization of the cells. With or without cell permeabilization, CEACAM1-L was detected in the ring-like structure shown in Figure 6b . This result suggests that CEACAM1-L remains at the cell surface but relocalizes from the cell ± cell contacts to a ring-like structure condensed at the top of the cell (Figure 6b , panels 7 ± 12). Staurosporine completely abolished the eect of PMA on cells expressing either wild-type (Figure 6a , panel 5) or Ser503 mutant CEACAM1-L (data not shown), whereas calphostin C treatment, prior to addition of PMA, did not alter the cell spreading or CEACAM1-L relocalization mediated by PMA ( Figure  6a , panel 6). Therefore, these results show that PMA treatment of mouse colon tumor cells expressing CEACAM1-L induced cell spreading and disappearance of CEACAM1-L from cell contacts. We have previously shown that CEACAM1-L is tightly associated with the actin cytoskeleton and was found in a 1% Triton X-100 insoluble fraction (Sadekova et al., 2000) . We then questioned whether the relocalization of CEACAM1-L changed its association to the cytoskeleton. As shown in Figure 6c , short (lanes 3 and 4) or prolonged (lanes 5 and 6) PMA treatment of cells did not modify the CEACAM1-L solubility, which remained in the 1% Triton X-100 insoluble fraction.
Discussion
CEACAM1 is an important member of the carcinoembryonic antigen (CEA) family . CEACAM1 plays a role in the development of many types of cancers. Its expression is dramatically reduced in the early phases of intestinal cancers (Neumaier et al., 1993; Rosenberg et al., 1993; Nollau et al., 1997; Ilantzis et al., 1997) . It is also downregulated in prostate cancer and is absent from hyperproliferative prostate tissue (Hsieh et al., 1995) .
Furthermore, CEACAM1's expression is absent in liver and endometrial carcinomas and in 30% of breast cancers (Tanaka et al., 1997; Bamberger et al., 1998; Huang et al., 1998) . CEACAM1 expresses two cytoplasmic variants; a short 10 amino acid cytoplasmic domain and a longer variant of 71 ± 73 amino acids (Beauchemin et al., 1998) . We and others have demonstrated that expression in tumorigenic cells of the longer CEACAM1 variant resulted in in vivo growth inhibition of colon, prostate and breast cancers (Kunath et al., 1995; Hsieh et al., 1995; Luo et al., 1997) . This phenotype was valid providing that the expression levels of the CEACAM1-L protein were comparable to that found in normal tissue . We have also shown that the dynamics of CEACAM1-L Tyr phosphorylation and dephosphorylation are crucial for inhibition of tumor cell growth since mutation of Tyr488 resulted in tumor development . In addition, deletion of the three terminal Lys residues, involved in the regulation of CEACAM1-L Tyr phosphorylation (Huber et al., 1999) , produced a similar phenotype . This suggested that either intramolecular connections between dierent regions of the cytoplasmic domain were necessary for ecient folding of the protein or that intermolecular associations with dierent key players in signaling cascades depended on the presence and phosphorylation of the Tyr488 residue.
There are 17 Ser/Thr in the cytoplasmic domain, many of these residues being located in consensus sites for a variety of Ser/Thr protein kinases. Ser503 has been shown to play a crucial role in CEACAM1-Lmediated processes such as insulin receptor internalization or bile salt extrusion (Sippel et al., 1994) . For this reason, we focused our investigation on the role played by Ser503 in CEACAM1-L-mediated tumor growth inhibition. Our results demonstrate that mutation of the Ser503 residue to an Ala aected the in vivo inhibition of tumor development usually observed with cells expressing the wild-type CEACAM1-L.
We then considered potential mechanisms involved in the Ser503-directed reversal of tumor growth inhibition and ®rst focused on Ser phosphorylation. CEACAM1-L is basally phosphorylated on Ser/Thr residues in epithelial cells. Similar results had been obtained in ®broblast and epithelial models (Odin et al., 1986; McEntire et al., 1989; Culic et al., 1992; Sippel et al., 1994; Najjar et al., 1995) . We demonstrated that phorbol ester-mediated activation of kinase(s) led to increased phosphorylation of the CEACAM1-L protein. As PMA is a known activator of protein kinase C (Newton, 1994) , we examined whether this kinase was indeed responsible for the phosphorylation of the long cytoplasmic domain. Our results with the PKC inhibitors calphostin C, H7 and sphingosine demonstrate that PKC had no obvious eect on in vivo phosphorylation of CEACAM1-L expressed in mouse cells. This was in spite of the fact that a CEACAM1-L membrane-proximal PKC site is phosphorylated in vitro by puri®ed isoforms of PKC.
In vivo, however, dierences in overall Ser phosphorylation levels might not be apparent when so many sites are available for phosphorylation. On the other hand, this discrepancy between the in vitro and in vivo phosphorylation data might also result from the unavailability or masking of the PKC membraneproximal site. Instead of PKC, it is likely that dierent staurosporine-sensitive Ser/Thr kinases, other than calmodulin kinase and protein kinase A, are likely eective. In vivo experiments revealed that both CEACAM1-L and its Ser503 mutant responded to PMA treatment. Proteolytic maps of the in vivo 32 Plabeled wild-type and Ser mutant CEACAM1-L proteins will be needed to ascertain which sites are targets for the various kinases. Hence, the precise CEACAM1-L Ser phosphorylation site(s) or speci®c kinase(s) provoking PMA-mediated increased CEACAM1-L phosphorylation remain to be identi®ed.
Interestingly, both Tyr488 and Ser503 are needed for insulin receptor internalization . In this context, mitogenic responses to insulin were enhanced in cells transfected with either the Tyr488 or Ser503 mutants. This is in agreement with the in vivo tumor assays with CT51 cells expressing either of these mutants and this study) and it appears that a delicate balance is established between these two residues to regulate tumor cell growth. One model to explain our tumor inhibition data would be that the conformation of the cytoplasmic domain might vary depending on its binding to a number of protein complexes. Steric hindrance may need to be considered i.e. occupancy of one site by a protein complex might restrict accessibility of the other site to its own signaling complex. We have shown that Tyr488 is required for binding of the Tyr phosphatases SHP-1 and SHP-2 Huber et al., 1999) . It has also been shown for instance that the 35 distal amino acids (including Ser503) of the rat CEACAM1-L cytoplasmic domain associate with an 80 kDa protein (CAP-80). Ser503 may be crucial for the binding of this protein since a deletion mutant truncating the protein at Lys499, thereby eliminating Ser503, no longer had the capability of binding the CAP-80 protein. Although its identity is still unknown, CAP-80 appears important in the CEACAM1-L Ser503-dependent growth suppressive eects (Luo et al., 1998) . In addition, tight association of CEACAM1-L with the actin cytoskeleton is mediated by the same 35 distal amino acids (Sadekova et al., 2000) .
A second potential mechanism to explain the involvement of Ser503 in the CEACAM1-L-mediated tumor suppressive phenotype is the CEACAM1-L cellular localization. We have not seen any dierences in localization between the wild-type and the Ser503-expressing CEACAM1-L. However, the localization of CEACAM1-L is not static. In normal colon tissue, CEACAM1 is generally concentrated at the luminal glycocalyx and fuzzy coat of epithelial cells (FraÈ ngsmyr et al., 1995) . The protein is also localized to the lateral borders of enterocytes (Hansson et al., 1989) . Additionally, in serum-starved ®broblasts, CEACAM1-L is predominantly found in the cytoplasm (Sadekova et al., 2000) . In these cells, it undergoes translocation to the cell membrane where it engages in cell adhesion upon activation of Rac1, RhoA or Cdc42. This process requires association of CEACAM1-L with polymerized actin and reorganization of the actin cytoskeleton provoked relocalization of CEACAM1-L (Sadekova et al., 2000) . We have recently observed similar dierences in localization of CEACAM1 depending on activation of the Rho-like GTPases in MDCK cells (FourneÁ s et al., in preparation) . As shown in Figure 6 , CT51 CEACAM1-Ltransfected cells also undergo cell spreading and relocalization of CEACAM1-L in response to PMA treatment. In these conditions, CEACAM1-L is tightly associated with cortical actin and its relocalization is correlated with that of the actin cytoskeleton. As PMA is also known to provoke a number of cellular modi®cations (Newton, 1994) , there remains a possibility that the CEACAM1-L-associated phenotypes may be due to a bystander eect. Not much is known about directed targeting of cell adhesion molecules. Recent data on co-localization of E-cadherin and the c-Met receptor have indicated that PMA treatment of MDCK cells caused cell spreading leading to the concomitant disappearance of these proteins from the sites of cell ± cell adhesion. After a prolonged PMA treatment, they are found within the late endosomes (Kamei et al., 1999) . This process is linked to cytoskeletal reorganizations via activation or inhibition of a number of Rho-like GTPases (Imamura et al., 1998; Kamei et al., 1999) . Thus, a dynamic trac established between cytoplasmic or cell surface localization of CEACAM1-L is becoming more apparent than had previously been observed. Whether PMA treatment ®rst aects the CEACAM1-L phosphorylation or whether it directly or indirectly in¯uences cytoskeletal plasticity resulting in alterations in cell shape will require further investigations. CEACAM1's dynamic transport to and from the cell membrane with disruption and reorganization of cytoskeletal components will also need to be considered.
Materials and methods
Cell culture
Human embryonic kidney (HEK293) cells were obtained from the American Tissue Culture Collection (ATCC CRL1573) and grown in a-minimal essential medium supplemented with 2 mM glutamine and 10% heat-inactivated fetal bovine serum at 378C in a humidi®ed atmosphere of 5% CO 2 . HEK293 cells (5610 5 cells per 100 mm dish) were transfected with 5 mg/100 mm dish of the pXM139-CEACAM1-L-expressing plasmid DNA using calcium phosphate co-precipitation (Southern and Berg, 1982) . Growth of CT51 mouse colon carcinoma cells, generously provided by Dr Michael Brattain (Medical College of Ohio, Toledo, Ohio, USA) and insertion of the CEACAM1-L or mutant cDNA constructs by retroviral-mediated infection have previously been described (Kunath et al., 1995) . Cell clones were manually selected from G418-resistant populations (G418: 1.5 mg/ml) and CEACAM1-L-positive clones were identi®ed by FACS analyses and immunoblotting as previously described (Kunath et al., 1995) . The mouse liver carcinoma cell line, BNL1MEA.7R.1 (ATCC: TIB 75), is a methylcholanthracene epoxide-transformed mouse liver cell line derived from the normal BALB/c embryonic liver cell line BNL CL.2 (ATCC: TIB 73). This cell line was transfected with the CEACAM1-L cDNA construct by retroviral-mediated transductions using a protocol similar to that reported in Kunath et al. (1995) . Metabolic labeling of HEK293, CT51 cells or BNL 1MEA cells was performed for 2 h with 200 mCi of 32 P-orthophosphate (NEN Dupont)/ 100 mm dishes in 2 ml of phosphate-free medium containing 2.0% dialysed FBS (Gibco). PMA, or inhibitor treatments (all purchased from Sigma) were performed at respective concentrations of: 25 ± 1000 nM of PMA for 10 min, 1 or 5 mM of staurosporine, 1 mM of calphostin C, 73 mM of H7, 10 mM of sphingosine, respectively for 15 min. Cells were also treated with cell permeable protein kinase inhibitors of calmodulin kinase (KN-62, 2 mM for 15 min) and of protein kinase A (RP-cAMP, 150 mM for 15 min). After treatment, cells were scraped from the dishes in the presence of lysis buer (600 ml/100 mm) containing 100 mM Tris-HCl (pH 8.0), 10 mM EDTA, 2% NP-40, 20 mg/ml of protease inhibitors (leupeptin, aprotinin, phenylmethylsulfonyl¯uor-ide, N-a-p-tosyl-1-lysine chloromethyl ketone, N-tosyl-1-phenylalanine chloromethyl ketone), 100 mM sodium¯uor-ide and 2 mM sodium orthovanadate. After centrifugation (1500 r.p.m.) for 5 min at 48C to remove cellular debris, protein content of cell lysates was measured using the BCA protein assay kit (Pierce Chemicals). Three separate experiments were performed using at least two cell clones of CT51-and MEA-transduced cells.
Site-directed mutagenesis and preparation of bacterial fusion proteins
Deletion and point mutants used in this study have been previously described (Huber et al., 1999) . The CEACAM1 mutated constructs were reintroduced into the pLXSN or pXM139 vectors used in stable or transient transfection assays. The cytoplasmic domains of CEACAM1 mutants were ampli®ed by PCR and cloned in frame into the pGEX2T vector. All mutated constructs were subjected to DNA sequence analysis to con®rm their integrity. Fusion protein constructs were introduced into E. coli BL21 bacteria and induction of expression and puri®cation of the GST proteins were performed according to standard procedures .
In vitro phosphorylation reactions
In vitro phosphorylation was performed by incubating 100 ng of the CEACAM1 cytoplasmic domain GST fusion proteins with 10 ng of a mixture of puri®ed a, b, and g protein kinase C isoforms (Calbiochem) in 20 ml of buer containing 20 mM Tris-HCl, pH 7.5, 0.1 mM CaCl 2 , 5 mM MgCl 2 , 0.03% Triton X-100 and 1 ml of g-labeled 32 P-ATP (6000 Ci/mmole, Amersham Corp.) for 30 min at 378C. Reactions were terminated by addition of 2 ml of loading dye buer and boiling for 10 min. The labeled proteins were separated on 10% polyacrylamide gels and subjected to autoradiography. The amount of GST fusion proteins used in each reaction was controlled by immunoblotting with an anti-GST antibody (Pharmacia).
Tryptic maps of GST fusion-CEACAM1
GST fusion proteins were labeled as described above and subjected to trypsin cleavage according to van der Geer et al. (1994) . Digested peptides were spotted on thin layer chromatography plates, and electrophoresed in the ®rst dimension in a pH 1.9 buer. After drying, the peptides were separated in the second dimension by chromatography as previously described (van der Geer et al., 1994) . Dried plates were then exposed to BioMax ®lms (Kodak).
Immunoprecipitation and immunoblotting
A polyclonal anti-mouse CEACAM1 antibody (Ab 231 or 2456), speci®c to the ®rst extracytoplasmic Ig domains of CEACAM1 (Daniels et al., 1996) or a monoclonal Ab (CC1) speci®c to the ®rst Ig domain of this protein (Dveksler et al., 1993) , have previously been described. Total cell lysate proteins (500 mg ± 1 mg) were immunoprecipitated with indicated antibodies at 48C for 2 h and immune complexes were adsorbed onto protein A or G Sepharose beads. Proteins were resolved on 8% SDS ± PAGE gels. For immunoblotting, proteins were transferred to Immobilon membranes. After blocking unspeci®c sites for 30 min at 208C with 5% milk/TBS, membranes were incubated with a 1 : 1000 dilution of anti-CEACAM1 antibodies. Immune complexes were visualized by incubating the membranes with an HRP-coupled anti-rabbit antibody and ECL detection (Amersham). Alternatively, 32 P-labeled proteins were exposed to X-ray ®lms.
Solubility assays
To determine whether CEACAM1-L was associated with the soluble or insoluble fractions, cells were treated as previously described (Sadekova et al., 2000) .
Immunofluorescence
Immuno¯uorescence detection was done essentially as described in Lamarche et al. (1996) . In brief, cells were rinsed in PBS, ®xed in 1.8% paraformaldehyde for 10 min and permeabilized in 0.2% Triton X-100/PBS for 5 min. Coverslips were incubated in 10% BSA for 45 min, then further incubated for 2 h with the anti-CEACAM1 primary antibody (Ab 2456, 1 : 800 dilution) diluted in PBS/5% BSA, washed with PBS/2% Triton X-100 and transferred to the appropriate secondary antibody (Cy3-conjugated goat antirabbit, 1 : 300 dilution) for 1 h. Coverslips were mounted with moviol containing p-phenylenediamine (1 mg/ml). The coverslips were examined with either a Zeiss Axiophot¯uorescence microscope or a BioRad confocal microscope.
Quantification
Quanti®cation of the radioactive bands was performed using a Fuji BioAnalyzing System 2000.
Tumor proliferation assays
In vivo tumor development was monitored for a period of 42 ± 56 days after injection of 4610 6 CT51 cell populations into the¯ank of 6-week-old BALB/c female mice. Ten mice were used per conditions tested. The weight and dimensions of the tumors were recorded. Statistical analyses were performed as previously described (Kunath et al., 1995) .
Abbreviations N-CAM, neural cell adhesion molecule; CEA, carcinoembryonic antigen; Bgp or BGP, biliary glycoprotein; CEACAM1; carcinoembryonic antigen cell adhesion molecule 1; TPA or PMA, phorbol 12-myristate 13-acetate; PKC, protein kinase C; MDCK, Mardin-Darby canine kidney cells; VEGF, vascular endothelial growth factor; PCR, polymerase chain reaction.
